TRK inhibitors in cancer therapeutics: Recent advances and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Tropomyosin receptor kinase (TRK) proteins are key regulators of cellular processes, implicated in cancer proliferation and survival.
• Dysregulated TRK signaling and acquired resistance mutations pose significant challenges in cancer therapy.
• Existing treatments may cause off-target effects, necessitating the development of selective inhibitors.

Purpose of the Study:

• To review recent progress in the development of small molecular TRK inhibitors.
• To summarize diverse structural types, activities, and selectivity profiles of novel TRK inhibitors.
• To identify promising TRK inhibitors for overcoming acquired resistance and improving therapeutic outcomes.

Main Methods:

• Literature review of recent scientific publications and clinical trial data.
• Analysis of structural diversity and pharmacological activity of small molecule TRK inhibitors.
• Evaluation of selectivity and potential for overcoming resistance mechanisms.

Main Results:

• Several novel small molecular TRK inhibitors with varied structures and high selectivity have been developed.
• These inhibitors demonstrate promising activity against TRK-driven cancers and potential to overcome acquired resistance.
• Recent advancements show improved safety profiles, addressing off-target effects.

Conclusions:

• Selective TRK inhibitors represent a promising therapeutic strategy for various cancers.
• Continued research into novel TRK inhibitors is crucial for addressing treatment resistance and enhancing patient outcomes.
• Small molecules targeting TRK signaling offer a pathway to more effective and safer cancer therapies.